Suchen
Jazz Pharmaceuticals PLC
JAZZZur Watchlist hinzufügen
252.860USD
-5.520-2.14%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
15.53BMarktkapitalisierung
613.23KGV TTM
mehr Informationen über Jazz Pharmaceuticals PLC Unternehmen
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLC Informationen
BörsenkürzelJAZZ
Name des UnternehmensJazz Pharmaceuticals PLC
IPO-datumJan 18, 2012
CEOGala (Renee D)
Anzahl der mitarbeiter2800
WertpapierartOrdinary Share
GeschäftsjahresendeJan 18
AddresseFifth Floor, Waterloo Exchange
StadtDUBLIN
BörseNASDAQ OMX - NASDAQ BASIC
LandIreland
Postleitzahl- -
Telefon35316347800
Websitehttps://www.jazzpharma.com/
BörsenkürzelJAZZ
IPO-datumJan 18, 2012
CEOGala (Renee D)
Führungskräfte von Jazz Pharmaceuticals PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
20.26K
-12.47%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
17.65K
+30.00%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
16.50K
+21.25%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
10.84K
+32.36%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Jazz Pharmaceuticals PLC?
Die fünf größten Anteilseigner von Jazz Pharmaceuticals PLC sind: Mr. Seamus C. Mulligan
Wie viele Institutionen halten Anteile an Jazz Pharmaceuticals PLC (JAZZ)?
Mit Stand vom 2026Q1 halten 1229 Institutionen Anteile an Jazz Pharmaceuticals PLC, mit einem Gesamtmarktwert von etwa 70.31M, was 112.06% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -754072.00 gestiegen.
Was ist die größte Einnahmequelle von Jazz Pharmaceuticals PLC?
Am 2026Q1 erzielte das Geschäft mit Xywav für Jazz Pharmaceuticals PLC den höchsten Umsatz in Höhe von 1.66B, was 38.83% des Gesamtumsatzes entspricht.